Market Herald logo


Be the first with the news that moves the market

Noxopharm has released data from its first set of pre-clinical studies and has confirmed idronoxil (IDX), used in the anti-cancer drug (Veyonda), activates the immune system.

The results confirm IDX activates cells, in both the innate and adaptive immune systems, which increases natural killer and T-helper cells.

These activated cells are then able to attack and clear harmful cells from the body.

While other drugs are limited in their effectiveness, Veyonda targets a wide range of cancerous cells and CEO Greg van Wyk believes it will be beneficial in the future.

“Veyonda appears to be a truly versatile drug candidate, with these immune-oncology effects having the potential to complement its radio-enhancing and chemo-enhancing functions across a broad range of cancer types,” he said.

While the global market for immune checkpoints was US$10.5 billion in 2017, it is projected to reach US$56 billion by 2025, based on what the rate of advancement is currently like.

The discovery of Veyonda is a potential means of overcoming the restricted benefit of current anti-cancer drugs with future studies done by Noxopharm focusing on how it works.

Please find announcement attached here 

NOX by the numbers
More From The Market Herald

" Incannex Healthcare (ASX:IHL) lands ethics approval for psychedelic-based anxiety treatment trial

Incannex Healthcare (IHL) has spiked on the ASX today after landing important regulatory approvals to trial a psychedelic-based treatment for severe anxiety.

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in
Security Matters (ASX:SMX) - CEO, Haggai Alon

" Security Matters (ASX:SMX) increases customer receipts in Q3

Security Matters (SMX) has delivered a recap of its quarterly activities during the three months ending September 30 2021.
The Market Herald Video

" Identitii (ASX:ID8) raises $6m to pursue growth initiatives

Software firm Identitii (ID8) has raised $6 million in a placement to institutional investors as it looks to accelerate a number of current